267 related articles for article (PubMed ID: 30045945)
21. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Kojima K; Maeda A; Yoshimura M; Nishida Y; Kimura S
Oncotarget; 2016 Oct; 7(43):69625-69637. PubMed ID: 27626308
[TBL] [Abstract][Full Text] [Related]
22. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Tirode F; Surdez D; Ma X; Parker M; Le Deley MC; Bahrami A; Zhang Z; Lapouble E; Grossetête-Lalami S; Rusch M; Reynaud S; Rio-Frio T; Hedlund E; Wu G; Chen X; Pierron G; Oberlin O; Zaidi S; Lemmon G; Gupta P; Vadodaria B; Easton J; Gut M; Ding L; Mardis ER; Wilson RK; Shurtleff S; Laurence V; Michon J; Marec-Bérard P; Gut I; Downing J; Dyer M; Zhang J; Delattre O;
Cancer Discov; 2014 Nov; 4(11):1342-53. PubMed ID: 25223734
[TBL] [Abstract][Full Text] [Related]
23. CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma.
Tan K; Lu W; Chen F; Shi H; Ma Y; Chen Z; Wu W; Lv Z; Mo J
J Exp Clin Cancer Res; 2023 Sep; 42(1):250. PubMed ID: 37759224
[TBL] [Abstract][Full Text] [Related]
24. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
25. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Hou J; Cao X; Cheng Y; Wang X
Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
[TBL] [Abstract][Full Text] [Related]
26. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma.
Lynn M; Wang Y; Slater J; Shah N; Conroy J; Ennis S; Morris T; Betts DR; Fletcher JA; O'Sullivan MJ
Diagn Mol Pathol; 2013 Jun; 22(2):76-84. PubMed ID: 23628818
[TBL] [Abstract][Full Text] [Related]
27. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.
Johnson KM; Mahler NR; Saund RS; Theisen ER; Taslim C; Callender NW; Crow JC; Miller KR; Lessnick SL
Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9870-9875. PubMed ID: 28847958
[TBL] [Abstract][Full Text] [Related]
28. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.
Wang Q; Li J; Zhu J; Mao J; Duan C; Liang X; Zhu L; Zhu M; Zhang Z; Lin F; Guo R
Clin Transl Med; 2022 Jun; 12(6):e882. PubMed ID: 35692096
[TBL] [Abstract][Full Text] [Related]
30. The genomic landscape of pediatric Ewing sarcoma.
Crompton BD; Stewart C; Taylor-Weiner A; Alexe G; Kurek KC; Calicchio ML; Kiezun A; Carter SL; Shukla SA; Mehta SS; Thorner AR; de Torres C; Lavarino C; Suñol M; McKenna A; Sivachenko A; Cibulskis K; Lawrence MS; Stojanov P; Rosenberg M; Ambrogio L; Auclair D; Seepo S; Blumenstiel B; DeFelice M; Imaz-Rosshandler I; Schwarz-Cruz Y Celis A; Rivera MN; Rodriguez-Galindo C; Fleming MD; Golub TR; Getz G; Mora J; Stegmaier K
Cancer Discov; 2014 Nov; 4(11):1326-41. PubMed ID: 25186949
[TBL] [Abstract][Full Text] [Related]
31. Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Shukla N; Somwar R; Smith RS; Ambati S; Munoz S; Merchant M; D'Arcy P; Wang X; Kobos R; Antczak C; Bhinder B; Shum D; Radu C; Yang G; Taylor BS; Ng CK; Weigelt B; Khodos I; de Stanchina E; Reis-Filho JS; Ouerfelli O; Linder S; Djaballah H; Ladanyi M
Cancer Res; 2016 Aug; 76(15):4525-34. PubMed ID: 27256563
[TBL] [Abstract][Full Text] [Related]
32. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
[TBL] [Abstract][Full Text] [Related]
33. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
34. Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
Enache OM; Rendo V; Abdusamad M; Lam D; Davison D; Pal S; Currimjee N; Hess J; Pantel S; Nag A; Thorner AR; Doench JG; Vazquez F; Beroukhim R; Golub TR; Ben-David U
Nat Genet; 2020 Jul; 52(7):662-668. PubMed ID: 32424350
[TBL] [Abstract][Full Text] [Related]
35. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
36. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.
Pessetto ZY; Chen B; Alturkmani H; Hyter S; Flynn CA; Baltezor M; Ma Y; Rosenthal HG; Neville KA; Weir SJ; Butte AJ; Godwin AK
Oncotarget; 2017 Jan; 8(3):4079-4095. PubMed ID: 27863422
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.
Sun H; Lin DC; Cao Q; Pang B; Gae DD; Lee VKM; Lim HJ; Doan N; Said JW; Gery S; Chow M; Mayakonda A; Forscher C; Tyner JW; Koeffler HP
Clin Cancer Res; 2017 Aug; 23(15):4376-4387. PubMed ID: 28336564
[No Abstract] [Full Text] [Related]
38. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
40. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.
Hayashi M; Chu D; Meyer CF; Llosa NJ; McCarty G; Morris CD; Levin AS; Wolinsky JP; Albert CM; Steppan DA; Park BH; Loeb DM
Cancer; 2016 Oct; 122(19):3015-23. PubMed ID: 27351911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
